Scarica l'app Stockscreener
64.50
0.86%
0.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$63.98
Aprire:
$63.57
Volume 24 ore:
951.74K
Relative Volume:
0.20
Capitalizzazione di mercato:
$24.88B
Reddito:
$4.66B
Utile/perdita netta:
$836.30M
Rapporto P/E:
30.82
EPS:
2.093
Flusso di cassa netto:
$1.08B
1 W Prestazione:
+2.23%
1M Prestazione:
-3.61%
6M Prestazione:
-5.70%
1 anno Prestazione:
-5.89%
Intervallo 1D:
$63.34
$65.29
Intervallo di 1 settimana:
$60.82
$65.29
Portata 52W:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
64.47 | 24.69B | 4.66B | 836.30M | 1.08B | 2.093 |
ABT
Abbott Laboratories
|
96.86 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
340.30 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.57 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.81 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.26 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DexCom Projected to Grow Profits as Q1 2026 Earnings Date Approaches - HarianBasis.co
Dexcom Inc. stock (US2521311074): Is continuous glucose monitoring strong enough to unlock new upsid - AD HOC NEWS
DexCom’s Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Devon Energy Corp stock (US2521311074): Is its shale production edge strong enough to unlock new ups - AD HOC NEWS
Lobbying Update: $75,000 of DEXCOM lobbying was just disclosed - Quiver Quantitative
TWIN CITY PRIVATE WEALTH, LLC's DexCom Inc(DXCM) Holding History - GuruFocus
DexCom, Inc. $DXCM Shares Purchased by Moran Wealth Management LLC - MarketBeat
KBC Group NV Sells 133,500 Shares of DexCom, Inc. $DXCM - MarketBeat
Chicago Capital LLC Reduces Position in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Purchased by Assetmark Inc. - MarketBeat
TransMedics & Dexcom: Healthcare Stocks for Long-Term GrowthNews and Statistics - IndexBox
A Look at DexCom Inc (DXCM) After 4.5% Gain -- GF Value $109.11 vs Price $63.98 - GuruFocus
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Dexcom EVP Brown sells $107k in shares - Investing.com
Dexcom EVP Brown sells $107k in shares By Investing.com - Investing.com UK
Dexcom (DXCM) EVP sells 1,700 shares, still holds 111,204 - Stock Titan
Here's Why You Should Add DexCom Stock to Your Portfolio Now - TradingView
DexCom, Inc. $DXCM Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
3 Reasons Investors Love DexCom (DXCM) - Barchart
DEXCOM INC ($DXCM) President & CEO 2025 Pay Revealed - Quiver Quantitative
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
[ARS] DEXCOM INC SEC Filing - Stock Titan
Dexcom (NASDAQ: DXCM) posts growth, seeks votes on board, pay and auditor - Stock Titan
Michael Brown (DXCM) files Form 144 to sell 1,700 restricted shares - Stock Titan
DexCom (DXCM) Upgraded to Buy: Here's Why - Yahoo Finance
Sumitomo Mitsui Trust Group Inc. Sells 15,977 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Dexcom Inc. stock (US2521311074): Why does its continuous glucose monitoring edge matter more now? - AD HOC NEWS
Dexcom Inc. stock (US2521311074): Why does its CGM leadership matter more now for U.S. investors? - AD HOC NEWS
Here's Why DexCom (DXCM) is a Strong Growth Stock - Yahoo Finance
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Q4 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks - Yahoo Finance
BTIG Research Adjusts DexCom Price Target to $80 From $85, Maintains Buy Rating - marketscreener.com
DexCom Salaries - Comparably
Greenup Street Wealth Management Invests in DexCom - National Today
Greenup Street Wealth Management LLC Makes New Investment in DexCom, Inc. $DXCM - MarketBeat
Risk Analysis: Can DexCom Inc be the next market leader2026 Snapshot & Weekly High Return Opportunities - baoquankhu1.vn
Trend Recap: Can DexCom Inc be the next market leaderPortfolio Profit Report & High Accuracy Trade Alerts - baoquankhu1.vn
Wells Fargo Maintains DexCom (DXCM) Overweight Recommendation - MSN
DexCom (XSWX:DXCM) Other Assets for Banks - GuruFocus
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dexcom Inc. stock (US2521311074): Is continuous glucose monitoring strong enough to drive U.S. inves - AD HOC NEWS
DexCom Inc (NASDAQ:DXCM) Fits the Affordable Growth Investment Strategy - ChartMill
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
DexCom (DXCM) Is Up 5.5% After New G7 Reimbursement Wins And CEO Transition PlansWhat's Changed - Sahm
DXCM (DexCom) Future Policy Benefits - GuruFocus
Alert from law firm on Dexcom withdrawn - marketscreener.com
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) - The National Law Review
DXCM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Goldman Sachs Adjusts Price Target on DexCom to $82 From $83, Maintains Buy Rating - marketscreener.com
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.17%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):